Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine among Adults Older Than 60 Years: Real-World Experience
Mayan Gilboa, Michal Mandelboim, Victoria Indenbaum, Yaniv Lustig, Carmit Cohen, Galia Rahav, Keren Asraf, Sharon Amit, Hanaa Jaber, Ital Nemet, Limor Kliker, Erez Bar-Haim, Ella Mendelson, Ram Doolman, Carmit Rubin, Gili Regev-Yochay, Yitshak Kreiss
Research output: Contribution to journal › Article › peer-review
30Scopus
citations
Fingerprint
Dive into the research topics of 'Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine among Adults Older Than 60 Years: Real-World Experience'. Together they form a unique fingerprint.